Vinorelbine plus cisplatin in the treatment of 48 cases with advanced non-small-cell lung cancer
- VernacularTitle:长春瑞滨加顺铂治疗48例晚期非小细胞肺癌
- Author:
Cheng HUANG
- Publication Type:Journal Article
- Keywords:
vinorelbine;
cisplatin;
non-small-cell lung cancer;
combination chemotherapy
- From:China Oncology
1998;0(04):-
- CountryChina
- Language:Chinese
-
Abstract:
Purpose:To evaluate the efficacy of NP regimen (NVB and DDP) in advanced non-small-cell lung cancer (NSCLC). Methods:48 patients with advanced NSCLC were treated by NP regimen. All of them had stage Ⅲ-Ⅳ disease (22 of them were primary treatment, the others were subsequent treatment). The chemotherapy dosage of NVB was 25 mg/m2 iv. d1,5, That of DDP was 35 mg/m2 iv d1,3.Results:The overall response rate (RR) was 50%, medium response time 5.5 months, medium survival time 11 months. The RR of 22 patients with primary treatment was 63.6%. The other patients after multiple course therapy 38.5%. The major adverse effects were myelosuppression and vein inflammation drug infusion through deep vein could avoid the vein inflammation. Conclusions:Authors suggest that NP regimen is effective therapy for non-small-cell lung cancer and deserves further clinical observation.
